SCHEMBL25274716

SCHEMBL25274716

Cc1ccccc1-c1cc(=O)oc2nc(N(C)CCC(=O)O)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNA3 P22001 3/20 0.41
▸ RXRA P19793 3/20 0.40
▸ RXRB P28702 2/20 0.40
▸ RXRG P48443 1/20 0.40
▸ NR4A2 P43354 1/20 0.40
▸ S1PR4 O95977 1/20 0.37
▸ S1PR5 Q9H228 1/20 0.37
▸ MCHR1 Q99705 3/20 0.36
▸ KDM4E B2RXH2 3/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ HPGD P15428 3/20 0.36
▸ GLA P06280 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ S1PR1 P21453 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25226413 0.92 KCNA3 (0.39) KCNA3MCHR1KDM4EALDH1A1HPGD
SCHEMBL26182090 0.91 KCNA3 (0.37) KCNA3RXRARXRBRXRGNR4A2
SCHEMBL25275975 0.91 KCNA3 (0.38) KCNA3RXRARXRBRXRGNR4A2
SCHEMBL25229541 0.89 KCNA3 (0.42) KCNA3RXRARXRBRXRGNR4A2
SCHEMBL25271829 0.85 KCNA3 (0.38) KCNA3RXRARXRBRXRGNR4A2
SCHEMBL25227213 0.85 KCNA3 (0.43) KCNA3KDM4EALDH1A1HPGDGLA
SCHEMBL25277964 0.84 KCNA3 (0.38) KCNA3KDM4EALDH1A1HPGDCYP1A2
SCHEMBL25227266 0.84 KCNA3 (0.38) KCNA3KDM4EALDH1A1HPGDGLA
SCHEMBL25281739 0.84 KCNA3 (0.39) KCNA3RXRARXRBRXRGNR4A2
SCHEMBL25280942 0.84 GPBAR1 (0.42) KCNA3KDM4EALDH1A1HPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066377-A1 AMINO CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-02-27 — — US disclosed
WO-2023114539-A1 AMINO CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2023-06-22 — — WO disclosed
WO-2023114539-A1 AMINO CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2023-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066377-A1 AMINO CHROMEN-2-ONE MODULATORS OF POLRMT POLRMT, TFAM, POLM KCNA3 4324/4885RXRA 1185/4885RXRB 1215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback